This launch has been initiated by the company's US based subsidiary, Mylan Pharmaceuticals.
The company added XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day) is the generic version of Janssen Pharmaceuticals' ORTHO EVRA (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).
XULANE is reportedly indicated for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception.
For the 12 months ending 30 December 2013, ORTHO EVRA had US sales of approximately USD152.9m, according to IMS Health.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia